Update shared on05 Sep 2025
Fair value Increased 5.17%Analysts have raised GeneDx Holdings’ price target from $115.29 to $121.25, citing accelerating growth in rare disease testing, a first-mover advantage, expected boost from new pediatric testing guidelines, and a recent shift to profitability as key drivers.
Analyst Commentary
- Bullish analysts highlight GeneDx’s fast growth in the under-penetrated rare disease testing market.
- The company is recognized for a unique first-mover advantage in rare disease testing.
- Initiation of profitability marks an inflection point for the business.
- Recent American Academy of Pediatrics guidance is expected to accelerate adoption of exome and genome testing as the standard of care for pediatric rare diseases.
- Analysts see current share levels as a compelling entry point given strong growth prospects and recent positive news flow.
What's in the News
- GeneDx Holdings raised full-year 2024 revenue guidance to $400-$415 million from $360-$375 million.
- The company was dropped from multiple Russell indices, including Microcap, Small Cap, 2000, 2500, and 3000E Growth and Value benchmarks.
- New data from the SeqFirst study, in partnership with Seattle Children's, showed rapid exome/genome sequencing as a first-tier test for non-critical pediatric inpatients significantly reduced diagnostic times from 289 to 13 days, maintained a high diagnostic yield (>40%), and enabled earlier interventions.
- The American Academy of Pediatrics now recommends exome and genome sequencing as first-tier tests for children with global developmental delay or intellectual disability, promoting earlier and more accurate diagnoses; GeneDx is highlighted as a leader in delivering these genomic technologies.
Valuation Changes
Summary of Valuation Changes for GeneDx Holdings
- The Consensus Analyst Price Target has risen from $115.29 to $121.25.
- The Future P/E for GeneDx Holdings has significantly risen from 38.35x to 42.65x.
- The Net Profit Margin for GeneDx Holdings has fallen from 18.94% to 17.83%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.